Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 313

The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.

Multisite Investigation of Outcomes With Implementation of CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention

Open access
Cavallari, Larisa H., Lee, Craig R., Beitelshees, Amber L., Cooper-DeHoff, Rhonda M., Duarte, Julio D., Voora, Deepak, Kimmel, Stephen E., McDonough, Caitrin W., Gong, Yan, Dave, Chintan V., Pratt, Victoria M., Alestock, Tameka D., Anderson, R. David, Alsip, Jorge, Ardati, Amer K., Brott, Brigitta C., Brown, Lawrence, Chumnumwat, Supatat, Clare-Salzler, Michael J., Coons, James C., Denny, Joshua C., Dillon, Chrisly, Elsey, Amanda R., Hamadeh, Issam S., Harada, Shuko, Hillegass, William B., Hines, Lindsay, Horenstein, Richard B., Howell, Lucius A., Jeng, Linda J.B., Kelemen, Mark D., Lee, Yee Ming, Magvanjav, Oyunbileg, Montasser, May, Nelson, David R., Nutescu, Edith A., Nwaba, Devon C., Pakyz, Ruth E., Palmer, Kathleen, Peterson, Josh F., Pollin, Toni I., Quinn, Alison H., Robinson, Shawn W., Schub, Jamie, Skaar, Todd C., Smith, D. Max, Sriramoju, Vindhya B., Starostik, Petr, Stys, Tomasz P., Stevenson, James M., Varunok, Nicholas, Vesely, Mark R., Wake, Dyson T., Weck, Karen E., Weitzel, Kristin W., Wilke, Russell A., Willig, James, Zhao, Richard Y., Kreutz, Rolf P., Stouffer, George A., Empey, Philip E., Limdi, Nita A., Shuldiner, Alan R., Winterstein, Almut G., Johnson, Julie A.·2018·JACC: Cardiovascular Interventions

Abstract

OBJECTIVES This multi-center pragmatic investigation assessed outcomes following clinical implementation of CYP2C19 genotype-guided antiplatelet therapy after PCI. BACKGROUND CYP2C19 loss-of-function alleles impair clopidogrel effectiveness after percutaneous coronary intervention (PCI). METHODS After clinical genotyping, each institution recommended alternative antiplatelet therapy (prasugrel, ticagrelor) in PCI patients with a loss-of-function allele. Major adverse cardiovascular events (MACE, defined as myocardial infarction, stroke, or death) within 12 months of PCI were compared between patients with a loss-of-function allele prescribed clopidogrel versus alternative therapy. Risk was also compared between patients without a loss-of-function allele and loss-of-function allele carriers prescribed alternative therapy. Cox regression was performed, adjusting for group differences with inverse probability of treatment weights. RESULTS Among 1,815 patients, 572 (31.5%) had a loss-of-function allele. The risk for MACE was significantly higher in patients with a loss-of-function allele prescribed clopidogrel versus alternative therapy [23.4 vs. 8.7 per 100 patient-years; adjusted hazard ratio (HR): 2.26; 95% confidence interval (CI): 1.18 to 4.32; p=0.013]. Similar results were observed among 1,210 patients with an acute coronary syndrome at the time of PCI (adjusted HR: 2.87; 95% CI: 1.35 to 6.09, p=0.013). There was no difference in MACE between patients without a loss-of-function allele and loss-of-function allele carriers prescribed alternative therapy (adjusted HR: 1.14, 95% CI: 0.69 to 1.88, p=0.60). CONCLUSIONS These data from real-world observations demonstrate a higher risk for cardiovascular events in patients with a CYP2C19 loss-of-function allele if clopidogrel versus alternative therapy is prescribed. A future randomized study of genotype-guided antiplatelet therapy may be of value.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jcin.2017.07.022

Cites

34 of 34 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 34 references

Cited by

See all 313

Metadata

Authors
Cavallari, L. H., Lee, C. R., Beitelshees, A. L., Cooper-DeHoff, R. M., Duarte, J. D., Voora, D., Kimmel, S. E., McDonough, C. W., Gong, Y., Dave, C. V., Pratt, V. M., Alestock, T. D., Anderson, R. D., Alsip, J., Ardati, A. K., Brott, B. C., Brown, L., Chumnumwat, S., Clare-Salzler, M. J., Coons, J. C., Denny, J. C., Dillon, C., Elsey, A. R., Hamadeh, I. S., Harada, S., Hillegass, W. B., Hines, L., Horenstein, R. B., Howell, L. A., Jeng, L. J. B., Kelemen, M. D., Lee, Y. M., Magvanjav, O., Montasser, M., Nelson, D. R., Nutescu, E. A., Nwaba, D. C., Pakyz, R. E., Palmer, K., Peterson, J. F., Pollin, T. I., Quinn, A. H., Robinson, S. W., Schub, J., Skaar, T. C., Smith, D. M., Sriramoju, V. B., Starostik, P., Stys, T. P., Stevenson, J. M., Varunok, N., Vesely, M. R., Wake, D. T., Weck, K. E., Weitzel, K. W., Wilke, R. A., Willig, J., Zhao, R. Y., Kreutz, R. P., Stouffer, G. A., Empey, P. E., Limdi, N. A., Shuldiner, A. R., Winterstein, A. G., & Johnson, J. A.
Venue
JACC: Cardiovascular Interventions
Publisher
Elsevier BV
Published
2018-01
Volume
11
Issue
2
Pages
181-191
ISSN
  • 1876-7605 (ISSN-L)
  • 1936-8798
OpenAlex
W2766537985
Cited by
313
References
34
FWCI
23.37
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Multisite Investigation of Outcomes With Implementation of CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention. https://app.cochat.ai/papers/10.1016/j.jcin.2017.07.022
The paper
Cavallari, L. H., Lee, C. R., Beitelshees, A. L., Cooper-DeHoff, R. M., Duarte, J. D., Voora, D., Kimmel, S. E., McDonough, C. W., Gong, Y., Dave, C. V., Pratt, V. M., Alestock, T. D., Anderson, R. D., Alsip, J., Ardati, A. K., Brott, B. C., Brown, L., Chumnumwat, S., Clare-Salzler, M. J., . . . Johnson, J. A. (2018). Multisite Investigation of Outcomes With Implementation of CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions. https://doi.org/10.1016/j.jcin.2017.07.022

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.